Meeting
2014 ASCO Annual Meeting
Effect of combination of proteasome inhibitor marizomib and immunomodulatory agent pomalidomide on synergistic cytotoxicity in multiple myeloma.
Authors
Dharminder Chauhan
Dana-Farber Cancer Institute, Boston, MA
Dharminder Chauhan , Deepika Sharma Das , Arghya Ray , Paul G. Richardson , Mohit Trikha , Kenneth Carl Anderson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8588)
DOI
10.1200/jco.2014.32.15_suppl.8588
Abstract #
8588
Poster Bd #
275
Abstract Disclosures
Similar Posters
First Author: Rafael Fonseca
Poster
2017 ASCO Annual Meeting
Synergism of gambogenic acid with bortezomib induce apoptosis of multiple myeloma.
First Author: Runzhe Chen
First Author: Allison Distler
Poster
2014 ASCO Annual Meeting
![MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.](https://d201v5jt9ylckg.cloudfront.net/144/8608/96164/96164_poster_pv.jpg)
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
First Author: Paul G. Richardson